“You've heard of Ozempic. You've probably heard of Mounjaro. Maybe you've even heard people call these medications game changers, and they are. But the conversation almost always stops at one number. How much weight did you lose?”
“People were losing 10%, 12%, 15% of their body weight in a clinical trial. That was unprecedented for a medication. Then came tirzepatide, Mounjaro, zepbound. This was a dual agonist. It targeted GLP-1 and a second receptor called GIP, glucose-dependent insulinotropic polypeptide.”
“Prioritize leucine-rich sources, meat, eggs, even dairy. My preference is raw dairy. They are the most direct drivers of muscle protein synthesis. Resistance training, at least three sessions per week, incorporating compound movements, squats, deadlifts, rows, presses.”
“Human Podcast, where we dig into the real science behind longevity and disease prevention. Today, we're talking about GLP-1 medications specifically, how we got here, why the newest generation is unlike anything we've ever seen, and the two things every single person on these drugs needs to be doing that most prescribers are not even mentioning. Let's start with the history, because it matters.”
“About two decades ago, researchers figured out how to mimic that signal pharmacologically. The first generation of these drugs, semaglutide, sold as Ozempic and Wegovy, targeted the GLP-1 receptor alone, a single agonist, one signal, and the results were significant.”
“polypeptide. Two signals instead of one. The metabolic effect was stronger. Weight loss numbers climbed. And then came Retatrutide, which is a triple agonist, GLP-1, GIP, and now a third, the glucagon receptor.”
As referenced on air, with the quote and the moment. Reported, not evaluated.
“A 2024 review published in Endocrinology and Metabolism traced this full arc and reported that the phase two clinical trial for retatrutide at 12 milligrams produced 24.2% mean body weight loss at 48 weeks.”
“A 2024 review published in Diabetes, Obesity, and Metabolism examined lean body mass changes across GLP-1 clinical trials and found that in some studies, reductions in lean mass accounted for 40 to 60% of the total weight lost.”
“The same review from Mount Sinai and Harvard was direct. All patients on these medications should be in comprehensive programs that emphasize two things, adequate high-quality protein intake and resistance training.”